A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 18 Jul 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Gepotidacin (Primary) ; Mesylates
Indications Bacterial infections; Gonorrhoea; Skin and soft tissue infections; Urinary tract infections
Focus Adverse reactions; Pharmacokinetics
Sponsors GlaxoSmithKline; GSK

11 Oct 2021 Results assessing pharmacokinetics and safety of Gepotidacin (GSK2140944) in healthy adult and adolescent participants from NCT02853435 and NCT04079790 trials, published in the Antimicrobial Agents and Chemotherapy.
12 Feb 2020 Status changed from recruiting to completed.
10 Sep 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com